1. Home
  2. FEAM vs CING Comparison

FEAM vs CING Comparison

Compare FEAM & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 5E Advanced Materials Inc.

FEAM

5E Advanced Materials Inc.

HOLD

Current Price

$2.37

Market Cap

56.9M

Sector

Industrials

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$5.26

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEAM
CING
Founded
2016
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.9M
64.5M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
FEAM
CING
Price
$2.37
$5.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$6.38
$34.50
AVG Volume (30 Days)
516.1K
105.1K
Earning Date
05-20-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
63.80
56.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$3.16
52 Week High
$7.50
$11.89

Technical Indicators

Market Signals
Indicator
FEAM
CING
Relative Strength Index (RSI) 72.56 53.89
Support Level $1.54 $4.77
Resistance Level $2.59 $5.52
Average True Range (ATR) 0.15 0.24
MACD 0.09 -0.01
Stochastic Oscillator 92.30 65.91

Price Performance

Historical Comparison
FEAM
CING

About FEAM 5E Advanced Materials Inc.

5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: